Antimitotic Agents: all 5,052 studies that test it

Page 22 of 51. Open to participants first (616), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)Status unknownNCT05068141Phase 2
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingNCT05054439Phase 2
• TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerActive, not recruitingNCT05053750Early Phase 1
• PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast CancerCompletedNCT05052437Phase 1
• Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
• A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's SarcomaCompletedNCT05046314Phase 2
• Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedNCT05044871Phase 2
• Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19Status unknownNCT05038449Not applicable
• Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast CancerStatus unknownNCT05033769Phase 4
• A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Status unknownNCT05027204Phase 1/2
• Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)Active, not recruitingNCT05024773Phase 3
• Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived OrganoidsActive, not recruitingNCT05024734Phase 2
• Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With ObesityCompletedNCT05017571Phase 2
• TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Phase 2
• Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical CarcinomaStatus unknownNCT05013268Phase 1
• P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .WithdrawnNCT05008510Phase 2
• Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II StudyStatus unknownNCT05008237Phase 2
• XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT05005728Phase 2
• Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node MetastasisStatus unknownNCT05002686Phase 2/3
• A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaActive, not recruitingNCT04994132Phase 3
• A PK Study of Oraxol in Breast Cancer PatientsCompletedNCT04993040Phase 1
• Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of MelanomaStatus unknownNCT04979585Phase 2
• A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)WithdrawnNCT04974996Phase 1
• Mono Antiplatelet and Colchicine TherapyCompletedNCT04949516Phase 4
• A Study of N9 Chemotherapy in Children With NeuroblastomaActive, not recruitingNCT04947501Early Phase 1
• Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic CancerActive, not recruitingNCT04940286Phase 2
• Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerActive, not recruitingNCT04938583Phase 1/2
• Perioperative Chemotherapy in Gastric CancerTerminatedNCT04937738Phase 2
• The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04937673Phase 2
• Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid TumorsTerminatedNCT04931823Phase 1
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
• Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung CancerActive, not recruitingNCT04922658Phase 2
• Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell CarcinomaStatus unknownNCT04922450Phase 2
• The COlchicine HypERtENsion TrialActive, not recruitingNCT04916522Phase 2
• Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II StudyStatus unknownNCT04913571Phase 2
• Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid TumorsCompletedNCT04911907Phase 2
• Post-Ablation Pericarditis Reduction StudyCompletedNCT04906720Phase 2
• Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast CancerCompletedNCT04903652Phase 2
• Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid TumorsSuspendedNCT04890093Phase 1/2
• A Bioequivalence Study of Docetaxel Injection in Patients With Solid TumoursCompletedNCT04889599Phase 3
• Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)Status unknownNCT04888663Phase 1/2
• Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)Active, not recruitingNCT04884282Phase 2
• Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruitingNCT04884035Phase 1
• Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve ReplacementCompletedNCT04870424Phase 3
• Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate CancerStatus unknownNCT04869371Phase 2
• Effectiveness of Colchicine Among Patients With COVID-19 InfectionCompletedNCT04867226Phase 2
• Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT04862650Phase 2
• First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsActive, not recruitingNCT04858269Phase 2
• Colchicine in HFpEFTerminatedNCT04857931Phase 2
• Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation StudyActive, not recruitingNCT04850235Phase 1
• Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT)CompletedNCT04848857Phase 4
• Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant TherapyStatus unknownNCT04848454Phase 2
• Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentTerminatedNCT04844749Phase 3
• Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT04843098Phase 1/2
• Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric CancerCompletedNCT04835896Phase 1/2
• Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.Status unknownNCT04835064Phase 3
• Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 InhibitorActive, not recruitingNCT04831320Phase 2
• Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic CancerActive, not recruitingNCT04827953Phase 1/2
• POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast CancerWithdrawnNCT04826016Phase 1/2
• Colchicine and Post-COVID-19 Pulmonary FibrosisActive, not recruitingNCT04818489Phase 4
• Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic CancerStatus unknownNCT04814485Phase 2
• The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and TaxotereStatus unknownNCT04811118Phase 1
• Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid TumoursTerminatedNCT04810208Phase 1
• Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic CancerStatus unknownNCT04808687Phase 2
• Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell CarcinomaTerminatedNCT04804696Phase 2
• Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)CompletedNCT04798703Phase 1
• Concurent Chemoradiotherapy in Head and Neck CancersStatus unknownNCT04780750Phase 3
• Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast CancerStatus unknownNCT04780347Phase 2
• Docetaxel and Irinotecan in Gastric CancerCompletedNCT04770623Phase 2
• Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous TummorStatus unknownNCT04766827Phase 4
• Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)Active, not recruitingNCT04764227Phase 2
• Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal CarcinomatosisActive, not recruitingNCT04762953Phase 2
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive, not recruitingNCT04759586Phase 3
• Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast CancerActive, not recruitingNCT04759248Phase 2
• Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLCWithdrawnNCT04754815Phase 2
• Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Active, not recruitingNCT04753879Phase 2
• The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast CancerStatus unknownNCT04753177Phase 2/3
• Capivasertib China PK StudyCompletedNCT04742036Phase 1
• A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCActive, not recruitingNCT04736823Phase 2
• A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT04734262Phase 2
• A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast CancerCompletedNCT04732598Phase 3
• Combination Therapy for First Line Treatment of Advanced Cervical CancerStatus unknownNCT04731038Phase 1
• Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableStatus unknownNCT04730232Phase 2
• Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder CarcinomaStatus unknownNCT04730219Phase 2
• Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid CarcinomaStatus unknownNCT04725448Phase 2
• Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)CompletedNCT04724629Phase 3
• Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast CancerStatus unknownNCT04722718Phase 2
• Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsActive, not recruitingNCT04721015Phase 1
• Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic CancerStatus unknownNCT04718701Phase 2
• Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaActive, not recruitingNCT04718415Phase 2
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.SuspendedNCT04711161Phase 1
• A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04709276Phase 2
• TH1902 in Patients With Advanced Solid TumorsActive, not recruitingNCT04706962Phase 1
• Randomized Double-blind Trial to Study the Benefit of Colchicine in Patients With Acutely Decompensated Heart FailureCompletedNCT04705987Phase 3
• The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid TumorsTerminatedNCT04696848Phase 1/2
• A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract CancerStatus unknownNCT04692051Phase 2
• Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL StudyCompletedNCT04675528Phase 1
• A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesCompletedNCT04672928Phase 1
• Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19CompletedNCT04667780Phase 3

← Antimitotic Agents overview